<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01537250</url>
  </required_header>
  <id_info>
    <org_study_id>TG-873870-C-3</org_study_id>
    <nct_id>NCT01537250</nct_id>
  </id_info>
  <brief_title>Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TaiGen Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TaiGen Biotechnology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and population
      pharmacokinetics of oral nemonoxacin in community-acquired pneumonia (CAP) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate clinical efficacy, microbiological efficacy and safety of Nemonoxacin adult patients
      with community-acquired pneumonia (CAP); and

      A study on the population pharmacokinetics (PPK) of continuous oral administration of
      Nemonoxacin in adult patients with CAP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Per subject clinical cure rate</measure>
    <time_frame>16days</time_frame>
    <description>Clinical cure rate equals to number of clinical evaluable divided by number of clinical cured. If subject's clnical outcome is evaluable by principal invastigator, he/she is defined as clinical evaluable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Per subject microbiological cure rate</measure>
    <time_frame>16days</time_frame>
    <description>Microbiological cure rate equals to number of microbiological evaluable divided by number of eradicated or presumed eradicated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of nemonoxacin in CAP subjects</measure>
    <time_frame>3days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Nemonoxacin 750 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 750 mg 2 tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nemonoxacin 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nemonoxacin 500 mg 3 tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin 500 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 500 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500 mg placebol</intervention_name>
    <description>oral form,,once adily,7~10 days</description>
    <arm_group_label>Nemonoxacin 750 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500 mg placebol</intervention_name>
    <description>oral form,,once adily,7~10 days</description>
    <arm_group_label>Nemonoxacin 500 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nemonoxacin 3 tablets</intervention_name>
    <description>oral form,once daily,7~10 days</description>
    <arm_group_label>Levofloxacin 500 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age of 18~70, BMI â‰¥ 18 kg/m2

          2. Female patients must avoid pregnancy

          3. Patients who are clinically diagnosed with community-acquired pneumonia (CAP)

          4. Chest X-ray shows inflammatory exudation or infiltration image.

          5. Patients who used antibacterial agents (excluding quinolones) within 72 hours before

          6. The patient's disease condition permits oral administration

        Exclusion Criteria:

          1. Patients who have any of bronchiectasis and pulmonary disease.

          2. Hospitalized within 14 days before enrollment

          3. Have a history of allergy to any quinolone or fluoroquinolone antibiotic

          4. Patients who suffered uncontrolled mental disorders, epilepsy or central nervous
             system diseases.

          5. Renal, liver insufficiency

          6. Malabsorption syndrome or other gastrointestinal diseases

          7. Immune system diseases,such as a history of human immunodeficiency virus (HIV)
             infection,neutropenia or malignant tumor in the blood system or a solid organ, or
             removal of spleen

          8. Steroids longterm use, the dose is at least 20mg of prednisone daily

          9. Patients under critical condition.

         10. Shows significant abnormality of the cardiac conduction system (CCS) or other
             abnormalities, or prolonged QTc

         11. Have a medical history of prolonged QTc, or require concomitant medication of drugs
             that will lead to prolongation of QTc

         12. Patients who received chemotherapy or anti-tumor therapy within 6 months

         13. Alcohol abused or drugs banned

         14. Patients who used quinolones within two weeks before enrollment

         15. Donated more than 500ml of blood within 3 months

         16. co-medication of other antibacterial agents required.

         17. by investigators judgement,patient who increase the risk to the subjects or interfere
             with this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yingyuan Zhang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Huashan Hospital, Fundan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PLA Second Artillery General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhen Hospital, Capital Medical University Beijing</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daping Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fujian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial People's Hospital</name>
      <address>
        <city>Gansu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou Red Cross Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Sun Yat-sen</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guilin Medical College</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taihe Hospital in Shiyan City, Hubei Province</name>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Third Xiangya Hospital, Central South University</name>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinan Central Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital of China Medical University</name>
      <address>
        <city>Liaoning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing General Hospital of Nanjing Military Region</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Antibiotics,Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai,</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital ,Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Antibiotics, Huashan Hospital, Fundan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Pudong New Area, Oriental Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Shanxi</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Liberation Army General Hospital of Shenyang Military Region</name>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>ShenZhen</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University (Respiratory)</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>Wenzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan General Hospital of PLA Guangzhou Military Region</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Zhejiang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2012</study_first_submitted>
  <study_first_submitted_qc>February 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2012</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

